Simanjuntak, Jan Stepfely2024-02-012024-02-012023-09PerpustakaanElfitrahttps://repository.unri.ac.id/handle/123456789/11266Chalcone 1-(naphthalene-2-yl)-prop-2-en-1-on-3-(4-(2-morpholinetoxy)phenyl) (CLN- 2NFT-4OM) had been successfully synthesized via the Claisen-Schmidt reaction and followed by O-alkylation. The morpholine substituted chalcone compound was synthesized by stirring and heating at a temperature of 60-70°C for 14 hours and purified by recrystallization to produce a pale white crystalline solid with a yield of 63.74%. The structure of the target synthesis compound was analyzed and confirmed through UV, FTIR, LCMS, 1H-NMR, and 13C- NMR. The in silico test was carried out on CLN-2NFT- 4OM (5) as a breast anticancer agent through molecular docking of the estrogen receptor α (PDB ID:8DVB) with a positive control, namely 4-hydroxytamoxifen (4OHT). The results of the anticancer activity of CLN-2NFT-4OM and the positive control respectively through molecular docking analysis showed quite good inhibition of the estrogen receptor α by showing binding free energy (ΔGbind) data and an inhibition constant of -9.4 kcal/mol and 1.26 μM and -9.3 kcal/mol and 1.27 μM. These results are close enough between the target compound and the positive control indicating that the compound chalcone CLN- 2NFT-4OM has the potential to act as an inhibitor of estrogen receptor α which triggers as a cause of breast cancer.enanticancerchalconemorpholineArticle